S
ince President Richard Nixon declared war on cancer more than 40 years ago, there have been significant increases in the number of people who survive cancer. Alongside advances in screening, detection, and diagnosis, the development of targeted anticancer agents has been a major contributory factor to this success. We highlight some of the key developments that have shaped oncological practice in recent decades and those that will likely have a significant impact in the near future ( Figure 1 ).
Top 5 therapeutic developments

Monoclonal antibodies
Monoclonal antibodies (mAbs) are designed to specifically kill cancer cells by targeting tumorassociated antigens on their surface ( Table 1 ). The first drug of this kind to be approved by the Food and Drug Administration (FDA) was rituximab. This anti-CD20 mAb has revolutionized the treatment of B-cell lymphomas (on which the CD20 antigen is expressed), producing response rates over 90% in combination with the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy regimen. 1 There have also been notable advances in the use of mAbs in the treatment of solid tumors. Trastuzumab reduces recurrence rates by half when used in combination with chemotherapy in the 20%-30% of women with metastatic breast cancers that overexpress the HER2 (human epidermal growth factor receptor) protein. HER2-targeted therapy continues to provide breakthroughs; in 2012, pertuzumab, which has a synergistic effect when combined with trastuzumab, was approved.
mAbs work via several different cellular mechanisms, of which researchers are now gaining a better understanding, and increasingly effective agents with fewer side effects are being developed. 2, 3 Small-molecule inhibitors The most easily "druggable" targets for small-molecule inhibitors (SMIs) are kinases, particularly cell surface tyrosine kinase receptors, which initiate signaling cascades that drive important cellular processes. SMIs differ from mAbs in that they are administered orally rather than intravenously, are less specific, and require more frequent dosing.
Imatinib was the first agent of this kind and was also the first to target a specific molecular defect in cancer cells; a chromosomal translocation (Philadelphia chromosome) that resulted in the formation of the BCR-ABL fusion protein, a tyrosine kinase that is always active and therefore oncogenic. This defect is present in almost all patients with chronic myelogenous leukemia, so imatinib therapy results in a complete hematologic response in 98% of patients. Imatinib has also revolutionized the treatment of gastrointestinal stromal tumors, a rare abdominal cancer that was virtually untreatable before its approval. 2 There are at least 90 tyrosine kinases in the human genome 4 and many of these have now been targeted with inhibitors that are either approved (Table 2 ) or in various stages of development. tients receiving the conjugate was increased by more than 5 months, compared with patients receiving a combination of capecitabine and lapatinib. 5 Genentech alone has over 25 ADCs in the pipeline, and these are rapidly becoming an important component of cancer treatment, particularly as researchers begin to improve their design to maximize efficacy and limit toxic side effects. 6, 7 Identification of defects that drive different cancers Cancer-causing genetic changes are referred to as "driver" events because they confer a growth advantage to cancer cells and can be directly linked to the development of a cancer. Genome sequencing technology has allowed researchers to uncover many of these events. The most frequently altered gene in human cancer is p53. Other common mutations occur in the kinase enzymes that are essential to intracellular signaling pathways. Driver events also occur in the form of chromosomal rearrangements and gene overexpression, with 2 significant examples being the EML4-ALK fusion gene in non-smallcell lung cancer, and overexpression of the HER2 gene in breast cancer.
The identification of driver events has been instrumental in developing targeted therapies and assessing which patients benefit the most, and a number of tests have been approved by the FDA for this purpose (Table 3) . Continual assessment of the cancer genome is also important as subsequent mutations can develop in response to targeted therapy that may drive resistance. 
Inhibiting angiogenesis
Tumors require oxygen and nutrients from their surrounding environment to be able to grow and they initially obtain them through diffusion. However, they are unable to grow beyond 2 mm without stimulating the growth of new blood vessels (a process called angiogenesis) to provide for their growing needs. When ImaƟnib for the treatment of CML gains the fastest FDA approval in US history. It is the first agent to target a specific molecular defect -the Philadelphia chromosome.
A second radiotherapeuƟc anƟbody, I-131 tositumomab enters the market for NHL. The mAb alemtuzumab becomes available for the treatment of CLL.
The radiotherapeuƟc anƟbody ibritumomab Ɵuxetan is approved for the treatment of NHL.
The first agent targeƟng the EGFR, gefiƟnib revoluƟonizes the treatment of NSCLC.
The human genome is decoded paving the way for the idenƟficaƟon of new geneƟc defects driving cancer and improving diagnosis and treatment.
ErloƟnib becomes the second EGFR-targeted small molecule inhibitor available for the treatment of NSCLC.
The first anƟ-angiogenic agent, a mAb targeƟng VEGF, bevacizumab, is approved for the treatment of CRC.
An anƟ-EGFR mAb, Pannitumumab, is approved for the treatment of metastaƟc CRC and becomes the first agent to demonstrate the use of KRAS as a predicƟve biomarker.
The oncogenic BRAF mutaƟon is idenƟfied and found to be an important driver of certain malignancies, including melanoma.
The first conclusive evidence of cancer stem cells is published.
MutaƟons in the PIK3CA gene and EGFR gene are idenƟfied and shown to be important drivers of colon and lung cancer, respecƟvely.
MutaƟons in the ABL gene are idenƟfied.
A record number of Americans are shown to be surviving cancer according to NCI and CDC data.
Ipilimumab, a mAb targeƟng CTLA4, becomes the first cancer agent to target the immune system, in order to help paƟents with metastaƟc melanoma. The transforming EML4-ALK fusion gene is idenƟfied as an important driver of lung cancer.
A second EGFR-targeted mAb, cetuximab, is approved for the treatment of KRAS wild type CRC.
Ofatumumab is the first nonradiotherapeuƟc mAb targeƟng CD20 to be approved for the treatment of CLL.
The first therapeuƟc cancer vaccine, Sipleucel-T, is approved for the treatment of advanced prostate cancer.
The first anƟbody-drug conjugate, T-DM1, is approved by the FDA for the treatment of breast cancer. It combines the HER2 mAb with a cytotoxic agent (DM1).
Breast cancer survival is further improved by the introducƟon of a second HER2-targeƟng mAb, pertuzumab, to be used in combinaƟon with trastuzumab.
AcƟvaƟng mutaƟons in the HER2 gene are idenƟfied, which could mean that HER2-negaƟve paƟents also benefit from HER2-targeted agents.
The first inhibitor of mTOR , everolimus is granted approval by the FDA for the treatment of advanced RCC.
An androgen receptor inhibitor, enzalutamide is approved for the treatment of late-stage prostate cancer.
The first anƟ-cancer agent targeƟng a developmental pathway, the hedgehog inhibitor vismodegib is approved for paƟents with basal cell carcinoma. cells become cancerous they acquire certain "hallmark" abilities, one of which is the ability to stimulate angiogenesis. Clinical validation of angiogenesis as a target for cancer therapy came in 2003 with the approval of the mAb bevacizumab, which targets the vascular endothelial growth factor (VEGF), an important driver of angiogenic pathways. VEGF and its receptor VEGFR have been a very promising area of exploration and approved agents now include sorafenib, sunitinib, pazopanib, and, most recently, axitinib, which was approved for the treatment of renal cell carcinoma after it demonstrated a 2-month improvement in progression-free survival (PFS).
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Top 5 research developments 'Hallmarks' of cancer Hanahan and Weinberg suggested that there are 6 essential alterations in cell physiology 10 that allow the transformation of a normal cell into a malignant tumor. These so-called "hallmarks" of cancer include the cells' ability to sustain their own growth, avoid cell death, divide without limit, stimulate angiogenesis, and invade and metastasize (Figure 3) . The hallmarks were recently updated to reflect new research. Two new hallmarks were added (evasion of the immune system and reprogramming of cell metabolism) along with several "enabling characteristics," which must be fulfilled for a cell to begin acquiring hallmark abilities (genomic instability and tumorpromoting inflammation).
Traditionally, targeted cancer therapy was aimed at preventing the uncontrolled growth of cancer cells, but we are now beginning to branch out into targeting other hallmark abilities. Therapies that may begin to emerge in the future include those targeting the glycolytic pathway, with the aim of disrupting a cancer cell's ability to effect a metabolic change known as the Warburg effect (switching energy production from oxidative phosphorylation to glycolysis).
11
Genome sequencing Significant technological advances in the past several decades, such as the advent of "high throughput" and "next generation" sequencing have enabled researchers to rapidly and cost-effectively analyze entire genomes. This enables them to take the characterization of driver events of cancer to the next level and sequence the whole genome of a tumor for comparison with healthy tissue.
This technology can be used to examine a specific tumor type or subtype, the cells of the tumor microenvironment, a subset of cancer cells (ie, cancer stem cells), or the molecular signature associated with a particular tumor-related process. In the clinic, this translates into superior classification of tumors and tumor subtypes, identification of genes of diagnostic and therapeutic significance (driver events), and prediction of cancer risk and clinical outcomes. Ultimately, it may enable clinicians to really deliver on the potential of personalized medicine, so that we may see targeted therapies becoming standard of care and of benefit to all cancer patients. 8 
Tumor cell heterogeneity
We are now beginning to understand that tumors contain cells that are both phenotypically and functionally diverse and that this can have significant implications for targeted therapy. Different populations of cells within a tumor may respond differently to targeted therapies, not just because of genetic variation, but also epigenetic differences and the effects of the tumor microenvironment. The current paradigm for cancer treatment is to target underlying common features, but if each cancer is indeed unique it will require more individualized treatment.
One important population is that of cancer stem cells (CSCs), the progenitor cells from which all other cells of the tumor arise. CSCs potentially represent an important target for cancer therapy and may have implications for the application of existing targeted therapies. For example, recent research found that HER2-targeted treatments may work in HER2-negative breast cancer patients, as well as HER2-positive patients, in whom they are currently approved. A potential molecular mechanism for this finding is that HER2 is expressed by CSCs at levels that are beneath the threshold of detection for tests for HER2 positivity, but which still provide a target for HER2 therapy.
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Therapeutic cancer vaccines Therapeutic cancer vaccines are designed to generate a targeted, immune-mediated antitumor response either against a patient's own cells or tumor (patient specific) or against specific tumor-associated antigens (patient nonspecific). They represent one of several immunomodulatory strategies that are being used in the fight against cancer and, as researchers gain understanding of the immune antitumor response, they are becoming an increasingly effective and important treatment modality. The first therapeutic vaccine, sipuleucel-T, was approved by the FDA in 2010 for the treatment of metastatic castration-resistant prostate cancer after it demonstrated an improvement in overall survival of over 4 months. A number of other therapeutic vaccines are in phase 3 clinical trials, including PSA-TRICOM, BiovaxID, MAGE-A3, and nelipepimut-S, for the treatment of prostate cancer, non-Hodgkin lymphoma, non-small-cell lung cancer, and breast cancer, respectively.
13
Alternative targets
Because protein kinases play a vital role in intracellular signal transduction and are very readily "druggable," they have historically been an extremely attractive target for therapeutic intervention in cancer. Recent advances in technology, however, are making it possible to more easily target proteins besides kinases. A significant example is the tumor suppres-FIGURE 3 The hallmarks of cancer.
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Abbreviations: CTLA4, cytotoxic T-lymphocyte antigen-4; EGFR, epidermal growth factor receptor; HGF, hepatocyte growth factor; mAb, monoclonal antibody; PARP, Poly(ADP-ribose) polymerase; VEGF, vascular endothelial growth factor. sor protein, p53, which is mutated in more than half of all human cancers but, until recently, was not an "ideal" target for conventional methods of drug development.
Developments in drug candidate screening, chemistry and structure-based design have led to novel ways of targeting not easily druggable proteins like p53. For example, drugs are being developed that target vital interactions between proteins rather than the proteins themselves and researchers are also exploring the concept of synthetic lethality (the theory that combining 2 mutations that are nonlethal by themselves can lead to cell deaththus targeting a gene that is synthetic lethal to a cancer relevant mutation should specifically kill cancer cells).
